Objective-The dominant-negative mutation, P467L, in peroxisome proliferator-activated receptor- (PPAR) affects adipose tissue distribution, insulin sensitivity, and blood pressure in heterozygous humans. We hypothesized that the equivalent mutation, PPAR-P465L, in mice will worsen atherosclerosis. Methods and Results-Apolipoprotein E-null mice with and without PPAR-P465L mutation were bred in 129S6 inbred genetic background. Mild hypertension and lipodystrophy of PPAR-P465L persisted in the apolipoprotein E-null background. Glucose homeostasis was normal, but plasma adiponectin was significantly lower and resistin was higher in PPAR-P465L mice. Plasma cholesterol and lipoprotein distribution were not different, but plasma triglycerides tended to be reduced. Surprisingly, there were no overall changes in the atherosclerotic plaque size or composition. PPAR-P465L macrophages had a small decrease in CD36 mRNA and a small yet significant reduction in very-low-density lipoprotein uptake in culture. In unloaded apolipoprotein E-null macrophages with PPAR-P465L, cholesterol uptake was reduced whereas apolipoprotein AI-mediated efflux was increased. However, when cells were cholesterol loaded in the presence of acetylated low-density lipoprotein, no genotype difference in uptake or efflux was apparent. A reduction of vascular cell adhesion molecule-1 expression in aorta suggests a relatively antiatherogenic vascular environment in mice with PPAR-P465L.
M ost individuals with cardiovascular disease have multiple risk factors including dyslipidemia, hypertension, abdominal obesity, insulin resistance, and proinflammatory and prothrombotic state, which together constitute the metabolic syndrome. 1 Although insulin resistance is a significant component of metabolic syndrome, diabetes mellitus by itself can make patients more susceptible to atherosclerotic disease and also increases the severity of preexisting cardiovascular disease. Many patients with diabetes mellitus are being treated with peroxisome proliferator-activated receptor- (PPAR) agonist thiazolidinedione drugs, which act as insulin sensitizers. Multiple studies have demonstrated the antiatherosclerotic effects of PPAR agonists using mouse models of atherosclerosis lacking apolipoprotein E (apoE) or low-density lipoprotein receptor (LDLR). [2] [3] [4] PPAR is a nuclear receptor, and among its myriad functions, is necessary for adipocyte differentiation and triglyceride (TG) deposition. 5 The major site of expression of PPAR is in adipocytes, where 2 isoforms, PPAR1 and PPAR2, are transcribed. Although PPAR2 is adipocyte-specific and is the major form expressed in adipocytes, PPAR1 is expressed at lower levels in multiple cell types and has been detected in macrophage-derived foam cells in atherosclerotic plaques. 6 PPAR has emerged as an important regulator of scavenger receptor CD36, which can affect lipid accumulation in the macrophages. 7 On the other hand, PPAR has also been implicated in lipid efflux from macrophages through the activation of ATP-binding cassette transporter A1 (ABCA1). 8 Consistent with its role in efflux, high-fatfed LDLR-deficient mice reconstituted with bone marrow from mice with macrophage-specific deletion of PPAR had increased atherosclerosis compared with mice reconstituted with wild-type bone marrow. 8, 9 In the vasculature, PPAR1 isoform is expressed in endothelial cells and vascular smooth muscle cells, and plays a role in blood pressure (BP) regulation. 10 Also in high-fat-fed LDLR-deficient mice, endothelial cell-specific deletion of PPAR accelerated atherosclerosis, 11 and smooth muscle cell-specific PPAR disruption enhanced angiotensin II-induced atherosclerosis in males. 12 
Pro-and Antiatherogenic effects of a dominant-Negative P465L Mutation of Peroxisome Proliferator-Activated receptor-g in Apolipoprotein e-Null Mice
Although global lack of PPAR is incompatible with development and not observed in humans, there are polymorphisms that subtly affect its function. Among them are various point mutations that affect adipose tissue distribution and insulin sensitivity. For example, mutations in the ligand-binding domain at the C-terminus of the protein increase its binding to corepressors but impair binding to coactivators. 13 Because these mutant proteins retain DNA-binding ability, they cause dominant-negative reduction of PPAR activity in heterozygotes. One of these mutations, Pro to Leu substitution at position 467, was originally identified in patients with severe insulin resistance, hyperglycemia, lipodystrophy, and hypertension. 14 Mice heterozygous for the corresponding P465L mutation also have 8 mm Hg higher BP than normal and have mild hyperinsulinemia with an increased pancreatic islet mass particularly on high-fat diet. 15 However, they exhibit normal plasma glucose and insulin sensitivity, unless they are stressed by severe obesity 16 or by suppression of insulin production. 17 In the present study, we evaluated the effects of P465L mutation on the development of atherosclerosis in mice lacking apoE. Detrimental effects of the mutation on body fat distribution and BP are present in mice with apoE deficiency. Conversely, small, potentially atheroprotective changes were also detectable in macrophage lipid metabolism and vascular cell adhesion molecule-1 (VCAM-1) expression. Overall, however, the P465L mutation in PPAR exhibited no detectable effects on the atherosclerotic plaque development in the apoE-null mice.
Methods

Generation of Mutant Mice and diet
Pparg P465L/1 heterozygous mice 15 were crossed with apoE 2/2 mice, 18 both on the inbred 129S6/SvEvTac background. Pparg P465L/1 apoE 2/2 mice were crossed with apoE 2/2 mice to generate littermates with P465L mutation (L/1) or without (1/1) for experiments. Genotypes of mice were determined as previously described. 15 The mice were fed normal chow (NC; LabDiet 5P76; PMI Nutrition International) or a high-fat Western-type diet (HFW) containing 21% (w/w) fat and 0.15% (w/w) cholesterol (HFW; TD88137; Harlan Teklad). Animals were handled the following procedures approved by the Institutional Animal Care and Use Committee at The University of North Carolina at Chapel Hill.
BP Measurements
BP and pulse rate were measured by the tail-cuff method and were calculated from the mean of 30 daily measurements for 6 consecutive days. 19 
Glucose and lipid Metabolism
Animals were fasted for 4 hours before blood collection. Plasma glucose and cholesterol were measured by colorimetric assay (Wako Chemicals USA Inc). Plasma TGs were measured with reagents from Stanbio Laboratory. Glucose tolerance, liver TG secretion, and fat tolerance were determined on 4-to 5-month-old male mice of each genotype after 4-hour fast. 15, 20 Plasma insulin, resistin, and leptin were measured by multiplex immunoassays (Luminex), and adiponectin was measured by ELISA. 21 Males on HFW were treated with heparin (100 U/kg body weight), and plasma lipase activity was measured with 4-methylumbelliferyl heptanoate (RPI Corp) as described. 22 
Peritoneal Macrophage lipoprotein uptake and cholesterol efflux
Mice were given intraperitoneal injections of sterile 4% thioglycollate (BD Biosciences) in PBS. Four days later, macrophages were collected by peritoneal lavage into PBS. Macrophages were cultured in F-10 medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L l-glutamine. Verylow-density lipoproteins (VLDL) were isolated from apoE 2/2 mice, labeled with 1,1´-dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate (DiI C 18 ; Molecular Probes), and macrophage uptake of VLDL was measured as described. 23 For cholesterol efflux, peritoneal macrophages were cultured in a serum-free F-10 medium for 24 hours before incubation with 2-mCi/mL H 3 -cholesterol (Perkin-Elmer) with or without acetylated human LDL for 24 hours. Cells were washed and incubated in F-10 medium with or without 10 mg/mL of apoA1 (Sigma) for 24 hours. Efflux was calculated as a ratio of radioactivity in the medium divided by the total in cells and medium. 23
Bone Marrow Transfer
Bone marrow cells were collected from femurs and tibias of donor male mice by flushing with F-10 medium. ApoE 2/2 female recipients were lethally irradiated (9.5 grays) at 10 weeks of age, and injected with 210 6 bone marrow cells in 0.2 mL of medium through tail veins. 23
Atherosclerotic lesion
Mice were euthanized using an overdose of 2,2,2-bromophenol and perfused with heparinized PBS and 4% paraformaldehyde. The aortic root was serially sectioned and stained with Sudan IVB and hematoxylin. Atherosclerosis was scored as described. 18, 24 
Gene expression
Total RNA was purified from tissues using Automated Nucleic Acid Workstation ABI 6700, and real-time polymerase chain reaction was performed in ABI PRISM 7700 Sequence Detector (Applied Biosystems). -Actin mRNA was used for normalization. Primers and probe sets used are available in the online-only Data Supplement.
data Analysis
Values are reported as mean±SEM. Two-way ANOVA with genotype and sex as 2 factors was used for analyses. Student t test was used for comparisons between genotypes.
results
General Phenotypes and Glucose Metabolism
Pparg P465L/1 apoE 2/2 mice and Pparg 1/1 apoE 2/2 mice were born in the expected Mendelian ratio, appeared healthy and gained weight normally. General phenotypes of mice fed NC and HFW are summarized in Tables I and II in the online-only Data Supplement, respectively. BP of the Pparg P465L/1 apoE 2/2 mice was significantly elevated compared with Pparg 1/1 apoE 2/2 littermates by 8 mm Hg regardless of diet ( Figure 1A ; P456L effect P0.03 in NC and HFW). Thus, the hypertensive effects of the PPAR-P465L mutation are retained on the apoE-deficient background.
Previously, we identified that PPAR-P465L causes altered body fat distribution in mice, 15 and this effect was also present in mice on apoE-null background. Although animals had similar body weights and total body fat content, Pparg P465L/1 apoE 2/2 mice had a smaller visceral (perigonadal) adipose tissue mass but larger subcutaneous (inguinal) adipose tissue mass when compared with the corresponding fat depots in Pparg 1/1 apoE 2/2 mice ( Figure 1B) . Consequently, Pparg P465L/1 apoE 2/2 mice had a significantly higher inguinal to perigonadal ratio than the Pparg 1/1 apoE 2/2 littermate controls (Tables I and II in Figure 1C ; median area 1222 mm 2 versus 760 mm 2 ), suggesting that the cell number is not increased. Increased IF cell size is associated with increased expressions of lipoprotein lipase and resistin, and with decreased uncoupling protein 1. Expressions of adipocyte fatty acid-binding protein (adipocyte protein 2) and adiponectin were not different ( Figure 1D ). HFW increased the total amount of adipose tissue in both genotypes. However, fat distribution (IF/ perigonadal fat) ratio remained similar to that on NC diet (Tables I and II in the online-only Data Supplement).
Fasting plasma glucose levels were higher in male than female mice and higher in mice fed an HFW (Figure 2A ). The levels were slightly lower in Pparg P465L/1 apoE 2/2 mice than in Pparg 1/1 apoE 2/2 mice, but the overall genotype effect was not significant. Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 mice also handled a bolus of glucose equally well ( Figure 2B ). The fasted plasma insulin levels were not significantly different between the 2 genotypes ( Figure 2C ). PPAR regulates the expression of adipokines. Although plasma leptin levels were the same, resistin levels in the Pparg P465L/1 apoE 2/2 mice were 2-fold higher whereas adiponectin levels were 2-fold lower than in the Pparg 1/1 apoE 2/2 mice ( Figure 2D-2F ).
Together, these data demonstrate that the effects of PPAR-P465L on body fat distribution, BP regulation, and glucose metabolism persist in apoE-deficient mice. These phenotypes are well-known risk factors for atherosclerosis.
lipid Metabolism
ApoE deficiency causes plasma accumulation of cholesterolrich remnants of chylomicrons and VLDL. Plasma cholesterol was not different between the Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 mice on NC diet ( Table I in the online-only Data Supplement). Cholesterol levels increased 4-fold in both genotypes with HFW; however, there was no genotype difference ( Table II in the online-only Data Supplement). The overall distribution of plasma cholesterol among lipoproteins as assessed by fast protein liquid chromatography was also not different ( Figure 3A and 3B).
Fasted plasma TG levels tended to be slightly lower in the Pparg P465L/1 apoE 2/2 mice than in Pparg 1/1 apoE 2/2 mice on NC, although the difference was not statistically significant. Although plasma TG levels increased in both genotypes in response to HFW, the Pparg P465L/1 apoE 2/2 mice had a significantly smaller increase than the Pparg 1/1 apoE 2/2 controls, particularly in males ( Figure 3C ). Plasma TG values are a function of lipid absorption, rate of clearance, and liver TG synthesis and secretion. Despite the difference in plasma TG, the postprandial lipid handling as assessed by a lipid tolerance test ( Figure 3D ) and the secretion of TG from the livers measured under the inhibition of lipolysis by tyloxapol injection ( Figure  3E and 3F) were not different between the Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 mice regardless of diet. The difference in plasma TG may be explained by the higher lipoprotein lipase activity because Pparg P465L/1 apoE 2/2 IF tissues express 2.3 higher lipoprotein lipase ( Figure 1F ), but the total lipase activities in heparinized plasma were not different (data not shown).
Taken together, these data demonstrate that the hypercholesterolemia of apoE-null mice is not affected by the PPAR-P465L mutation. However, a trend of reduced plasma TG levels in the Pparg P465L/1 apoE 2/2 mice could protect them from atherosclerosis.
Atherosclerosis
We next measured the average size of atherosclerotic plaques in the aortic roots of 5-month-old NC-fed mice and 4-monthold HFW-fed mice for 2 months. Contrary to our expectation, the lesion size in Pparg 1/1 apoE 2/2 and Pparg P465L/1 apoE 2/2 mice did not differ in either dietary condition ( Figure 4A and 4B). Because our mice are 129S6 inbred background, they developed significant amount of plaques in the aortic arch, 18 but without detectable differences in the plaque covered areas between Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 (Tables I  and II in the online-only Data Supplement). The plaques in Pparg P465L/1 apoE 2/2 mice and Pparg 1/1 apoE 2/2 mice equally increased in size and complexity with age ( Figure 4C-4F) , and plaque compositions based on histological assessment of the occurrence of fibrous cap, necrotic core cholesterol clefts, and calcifications were similar (Table III in the online-only Data Supplement). Immunohistochemical staining of similar sized plaques for macrophages, T cells, and smooth muscle cells was not remarkably different ( Figure I in the online-only Data Supplement). Taken together, we conclude that the dominant-negative PPAR-P465L mutation has no effect on overall atherosclerotic plaque development in apoE-null mice.
Macrophage Function
Peritoneal macrophages from Pparg P465L/1 apoE 2/2 mice had a small but significant reduction (11%) in 1,1´-dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate-labeled VLDL uptake compared with the Pparg 1/1 apoE 2/2 controls ( Figure 5A ). Furthermore, when macrophages were incubated with 3 H-labeled cholesterol for 24 hours (unloaded), cholesterol incorporation into the cells was significantly lower at 75% ( Figure 5B ), and apoA1-stimulated cholesterol efflux by Pparg P465L/1 apoE 2/2 macrophages during the following 24 hours was significantly higher than Pparg 1/1 apoE 2/2 macrophages ( Figure 5C ). However, when the macrophages were loaded with cholesterol in the presence of acetylated human LDL to model foam cells (acetylated human LDLloaded), cholesterol incorporation and efflux were not different, and apoA1 equally stimulated cholesterol efflux from Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 macrophages.
To test the functions of Pparg P465L/1 apoE 2/2 macrophages in the atherosclerotic lesion development in vivo, we next harvested bone marrows from Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 male mice and transplanted them into 10-week-old Pparg 1/1 apoE 2/2 female recipients. Two months after the transfer, the size of the foam cell lesions in the aortic sinus of the mice that received Pparg P465L/1 apoE 2/2 bone marrow was not significantly different from those that received the Pparg 1/1 apoE 2/2 marrow ( Figure 5D ). Plaques were mostly of early stages of foam cell lesions in the recipients of bone marrows from either genotype (not shown).
Taken together, the presence of PPAR-P465L mutation reduced macrophage lipid accumulation and enhanced cholesterol efflux from unloaded macrophage. However, PPAR-P465L appears to have no effects on cholesterol efflux once foam cells are formed, and has little effects on atherosclerosis development in the hyperlipidemic apoEnull animals.
Macrophage and Vascular Gene expressions
Because macrophages lacking PPAR are reported to have impaired cholesterol efflux with reduced ABCA1 expression, we sought the effects of dominant-negative P465L mutation on the expression of genes important for cholesterol metabolism in macrophage ( Figure 6A ). We found a small increase in ABCA1 and a small decrease in CD36 in Pparg P465L/1 apoE 2/2 macrophages compared with Pparg 1/1 apoE 2/2 littermates, but the differences were not significant. Although 1,1´-dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate-VLDL uptake was reduced, genes that may influence VLDL uptake and cellular cholesterol contents in macrophage including scavenger receptor class B1 and LDLR were not different. VLDL receptor expression tended to be higher in Pparg P465L/1 apoE 2/2 macrophage, although again the difference was not statistically significant. Inflammatory response genes such as transforming growth factor-1, interleukin-6, and inducible NO synthase differed widely in individual macrophage isolates but were not significantly different between the 2 genotypes. Notably, at an individual animal basis, the level of CD36 expression is strongly and positively correlated with PPAR mRNA levels (r50.72) whereas it is negatively correlated with ABCA1 mRNA levels (r520.4; Figure 6B ). ABCA1 mRNA levels are in turn positively correlated with the inducible NO synthase gene expression (r50.68), suggesting that the inflammatory state of the macrophage as well as PPAR influence the expression of genes for lipid metabolism in macrophage.
To assess macrophage infiltration and vessel response, we next measured mRNA levels of genes in the aortic arches of Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 mice aged 3 months when foam cells just begin to accumulate in aortic arch ( Figure  6C) . No difference was found in the expression of a macrophage marker CD68, ABC transporter G1 that mediates free cholesterol efflux, or lipoprotein lipase, consistent with the histological observations. Expression of osteopontin (secreted phosphoprotein 1), ABCA1, and endothelial NO synthase in Pparg P465L/1 apoE 2/2 aortas trended higher than in Pparg 1/1 apoE 2/2 aortas. In contrast, the basal expression of VCAM-1 was significantly reduced to 40% in the Pparg P465L/1 apoE 2/2 compared with the Pparg 1/1 apoE 2/2 vessels. These findings suggest that the PPAR-P465L could be atheroprotective in aorta, but that macrophages accumulate in the vessels with a similar rate in Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 aortas in the early stage of plaque development.
discussion
PPAR has been implicated in the pathogenesis of atherosclerosis through its regulation of circulating lipid and glucose levels and also by modulating vascular cell functions. All the characteristics of the PPAR-P465L mutation previously observed in mice with wild-type apoE were present in Pparg P465L/1 apoE 2/2 mice, including increased BP, moderate hyperinsulinemia, and altered body fat distribution. Hypercholesterolemia of the apoE-null mice was not affected by the PPAR-P465L mutation. Overall, however, we observed no detectable differences in the size or complexities of the aortic root plaques in Pparg P465L/1 apoE 2/2 mice fed NC or 2 months of HFW, or in apoE 2/2 mice replaced with Pparg P465L/1 apoE 2/2 bone marrow. Our data unequivocally demonstrate that the dominant-negative PPAR-P465L mutation alone has no effect on plaque development in apoEdeficient mice.
Hypertension is a well-known risk factor for atherosclerosis. ApoE-null mice with elevated BP caused by genetic lack of endothelial NO synthase, 25 lack of natriuretic peptide receptor A, 26 or infusion of angiotensin II in circulation, 27 all develop enhanced atherosclerosis, which is attenuated by a reduction in BP. We therefore hypothesized that the elevated BP associated with the PPAR-P465L would accelerate atherosclerosis in Pparg P465L/1 apoE 2/2 mice. Although an 8-mm Hg increase is modest, hypertension in the Pparg P465L/1 apoE 2/2 mice is a potential proatherogenic factor. Yet, there was no enhanced atherosclerosis in the Pparg P465L/1 apoE 2/2 mice compared with the Pparg 1/1 apoE 2/2 mice. This suggests that either this degree of BP increase alone is not sufficient to promote atherogenesis, or the mechanism by which PPAR-P465L cause elevated BP is not directly relevant to plaque development. Cerebral arterioles expressing PPAR-P465L mutation show increased contraction to serotonin and endothelin 1, and impaired relaxation to acetylcholine. 28 However, response to acetylcholine is not impaired in aorta, implying that PPAR affects resistance vessels more than larger conduit vessels. 28 Further studies on the role of PPAR in the interaction between BP regulation and atherosclerosis are warranted.
Our Pparg P465L/1 apoE 2/2 mice have increased plasma resis tin and decreased plasma adiponectin; the profile associated with obesity, insulin resistance, and increased inflammatory diseases in subjects with metabolic syndrome. 29 Resistin antagonizes insulin function. Its expression is high in adipose tissues in rodents, and we found that its expression in IF in Pparg P465L/1 apoE 2/2 mice is elevated. Primary site of resistin expression in humans is mononuclear cells in blood and, although role of resistin in glucose homeostasis in humans is controversial and causative roles are yet to be established, resistin is strongly associated with inflammatory diseases, including atherosclerosis. 30 Adiponectin, in contrast, has insulin sensitizing and anti-inflammatory properties, and its expression is regulated by PPAR. Reduction of plasma adiponectin must be mainly the consequence of reduced production from the perigonadal fat, because adiponectin gene expression in IF of the Pparg P465L/1 apoE 2/2 mice was not altered. While IF mass in these mice was increased, individual adipocyte cell size is also increased resulting in unaltered total adipocyte number. Together, plasma adipokine profile of the Pparg P465L/1 apoE 2/2 mice is consistent with reduced PPAR activity and is suggestive of a proinflammatory state. However, the role of adiponectin in rodent atherosclerosis is controversial, because adenovirus-mediated adiponectin overproduction in the liver of apoE 2/2 mice reduced atherosclerosis 31 but neither deficiency nor overproduction altered atherosclerosis in LDLR 2/2 mice. 32 Some antiatherosclerotic factors may be counteracting the proatherogenic effects of high BP, lipodystrophy, and adipokine profile in the Pparg P465L/1 apoE 2/2 mice. For example, we established previously that mice with PPAR-P465L exhibit normal glucose handling, in part, because of increased release of postprandial insulin. 15, 17 When global insulin signaling is intact, increased insulin could be antiatherogenic, because insulin has vasodilatory and anti-inflammatory properties. 33 Consistent with this, loss of insulin signaling in vascular cells accelerated atherosclerosis 34 whereas chronic oral administration of insulin attenuated atherosclerosis. 35 Reduced plasma TG in the Pparg P465L/1 apoE 2/2 mice is also potentially antiatherogenic.
PPAR appears to play a complex and multifaceted role in macrophages, affecting the recruitment and activation of monocytes, cholesterol homeostasis, and inflammation. PPAR activation has been shown to increase the expression of scavenger receptor CD36, which is associated with lipid accumulation in the macrophage. 6, 7 For example, although the basal gene expression levels of CD36 were similar between wild-type and PPARdeficient macrophages, treatment of wild-type mice with rosiglitazone resulted in a robust upregulation of CD36 expression in a PPAR-dependent manner. 7 In our Pparg P465L/1 apoE 2/2 mice, the gene expression of CD36 in thioglycolate-induced macrophages was 25% lower than in Pparg 1/1 apoE 2/2 macrophages, with the difference approaching statistical significance. This reduction in basal gene expression likely contributes to the reduced lipid accumulation in the unloaded Pparg P465L/1 apoE 2/2 macrophages. In addition, we observed a significant reduction in 1,1´-dioctadecyl-3,3,3´,3´-tetramethylindocarbocyanine perchlorate-labeled VLDL uptake compared with macrophages isolated from the Pparg 1/1 apoE 2/2 mice.
PPAR activation also induces macrophage expression of ABCA1, and the conditional disruption of PPAR in murine macrophages reduces cholesterol efflux via reduction in ABCA1 transcription. 8 This mechanism may account for the 50% increase in atherosclerosis in both high-fat-fed wild-type C57BL/6 and LDLR-deficient mice reconstituted with bone marrow from mice with a macrophage-specific knockout of PPAR. 8, 9 In our study, the expression of ABCA1 in macrophage was slightly higher, if any, and unloaded Pparg P465L/1 apoE 2/2 macrophage had a 2-fold higher rates of cholesterol efflux. However, once the PPAR-P465L cells were loaded with acetylated cholesterol and became foam cell like, the enhanced ability of PPAR-P465L macrophages to efficiently efflux cholesterol compared with Pparg 1/1 apoE 2/2 controls disappeared. Although the reduced uptake and increased cholesterol efflux may point to an atheroprotective phenotype, the loss of advantage in efflux under excess cholesterol load may explain the lack of a reduction in the lesions in our bone marrow transfer experiments. Although the expression of CD36 in peritoneal macrophages was highly correlated with the levels of PPAR gene expression at individual isolate levels, we found that ABCA1 expression was not directly correlated with the PPAR gene expression. It was, instead, positively correlated with inducible NO synthase gene expression, suggesting the role of the inflammatory states in the regulation of ABCA1 gene in macrophages. This effect was, however, independent of PPAR-P467L mutation.
Consistent with histological observations, our analysis of gene expression in the aortic arch demonstrated that the recruitment and activation of macrophage in the vessel wall is not significantly different between Pparg P465L/1 apoE 2/2 and Pparg 1/1 apoE 2/2 mice at an early stage of atherosclerosis. An exception is that the expression of VCAM-1 was significantly lower in the Pparg P465L/1 apoE 2/2 vessels than in Pparg 1/1 apoE 2/2 vessels. VCAM-1 binds to 41 integrin, which is expressed on leukocytes, and mediates rolling and adhesion to endothelium. 36 The reduced expression of VCAM-1 could be antiatherogenic, because hypomorphic mutant form of VCAM-1 has been shown to protect LDLR-null mice from atherosclerosis. 36 In human atherosclerotic plaques, VCAM-1 is not expressed in normal vessels, but is focally expressed in endothelial cells and strongly in spindle-shaped cells of macrophage type in lipid-containing plaques. 37 However, because overall expression of macrophage markers including CD68 and secreted phosphoprotein 1 genes is not different between the 2 groups, the significance of a reduced VCAM-1 expression in the Pparg P465L/1 apoE 2/2 mice is not clear, and requires further study.
It is important to acknowledge that PPAR is identified as a crucial atheroprotective molecule primarily with a use of pharmacological drugs, which may exert PPAR-independent effects, or in the LDLR-null mice that lack PPAR in specific tissues while present in the rest of the body. Our genetic model is maintained on inbred 129/SvEv background, which ensures that no polymorphic variations present in different inbred mouse strains are accidentally segregating with the PPAR-P465L mutation and obscuring its effects. In this model, a reduction of PPAR function due to the P465L mutation affects the whole body, and therefore cross talks between different cell and organ systems are intact. Consequently, the balance between mild proatherogenic and antiatherogenic effects of the PPAR-P465L mutation can mutually dampen the potential deleterious effects in a single cell type or organ, as observed in the experiments of tissue-specific knockouts. The lack of demonstrable PPAR-P465L effects on atherosclerosis of the apoE-null mice can also be attributable to altered function of the mutant PPAR, because dominantnegative mutations are different from full deletion. Thus, severe hypercholesterolemia in apoE-deficient mice may not only mask small deleterious effects of PPAR-P465L, but may even increase the availability of some endogenous PPAR ligands, which allow overcome dominant-negative effects of P465L substitution. 38 Finally, we note that 1 of the atheroprotective roles of PPAR is an induction of apoE expression in macrophages which helps cholesterol efflux, 39, 40 and this induction is missing in apoE-null model. The possibility that the PPAR-P456L mutation may differentially alter the phenotype of some other model of atherosclerosis retaining endogenous apoE expression, such as LDLR-null mice, cannot be eliminated.
In conclusion, we found that the dominant-negative PPAR-P465L mutation has no overall effect on atherosclerotic plaque formation in apoE-null model. Although this specific mutation is rare in humans, its effects mimic those of other mutations and polymorphisms present in the human population.
